Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Lung cancer, non-small cell
Stage/Subtype:  stage IIIB non-small cell lung cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 177 for your search:
Start Over
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
Status: Active
Phase: Phase IV
Type: Treatment
Age: 70 and over
Trial IDs: ABI-007-NSCL-005, NCI-2014-02488, NCT02151149
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NLG0301, NCI-2013-00592, 1209-1184, NCT01774578
Standard or Accelerated Hypofractionated Image-Guided Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer and Poor Performance Status
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: STU 052011-093, NCI-2013-00783, NCT01459497
Comparing Photon Therapy To Proton Therapy To Treat Patients with Lung Cancer
Status: Active
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: RTOG-1308, NCI-2013-01850, NCT01993810
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ABI-007-NSCL-003, NCI-2014-01528, 2014-003804-66, NCT02027428
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 20 and over
Trial IDs: U31287-A-U301, NCI-2014-01446, NCT02134015
Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1302.5, NCI-2016-00374, 2014-002161-30, NCT02272413
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D5160C00007, NCI-2015-00219, 2014-002694-11, U1111-1160-2242, NCT02296125
Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D419AC00001, NCI-2015-02030, NCT02453282
Plinabulin (P) + Docetaxel (D) vs D as 2nd-Line Chemo in Patients With Advanced NSCLC With at Least 1 Large Lung Lesion
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BPI-2358-103, NCI-2015-01970, NCT02504489
Panobinostat and Pemetrexed Disodium in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 08-036, NCI-2011-02483, NCT00907179
Rilotumumab and Erlotinib Hydrochloride in Treating Patients With Recurrent or Progressive Advanced Non-Small Cell Lung Cancer Previously Treated With Chemotherapy
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 10-058, NCI-2011-02501, NCT01233687
Veliparib with or without Radiation Therapy, Carboplatin, and Paclitaxel in Patients with Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1206, NCI-2011-02592, CDR0000701003, CHNMC-PHII-111, PHII-111, 8811, NCT01386385
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CMEK162X2109, NCI-2012-00874, 2011-002578-21, NCT01449058
Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: M11VOL, NCI-2015-00776, NCT01543672
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B7461001, NCI-2014-00522, 2013-002620-17, NCT01970865
A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D4190C00006, NCI-2013-02416, 2015-003715-38, NCT02000947
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 3475-021, NCI-2014-00482, NCT02039674
Start Over